HTGCのニュース
Hercules Capital: This 11.7% Yielder Is Now My Largest BDC Position 2023/05/17 17:43:04 Seeking Alpha
Hercules Capital declared a total cash dividend of $0.47 per share for 1Q-23 at the beginning of May. Click here to read why HTGC stock is a Buy.
JMP Securities maintains Hercules Capital at Market Outperform with a price target of $15.00 2023/05/08 05:42:38 Investing.com
https://www.investing.com/news/pro/hercules-tech-growth-capital-receives-investment-bank-analyst-rating-update-3075420
Hercules Capital: I''m Harvesting This Terrific 12% Yield 2023/05/06 12:10:00 Seeking Alpha
Hercules Capital delivered strong Q1 2023 results, with growth in NII, debt yields, and assets under management. Click here to see why I rate HTGC stock a Buy.
Wells Fargo maintains Hercules Capital at Overweight with a price target of $13.50 2023/05/05 18:06:36 Investing.com
https://www.investing.com/news/pro/hercules-tech-growth-capital-receives-investment-bank-analyst-rating-update-3074744
Hercules Capital: We Are Buying Investment Grade Bonds Yielding 7.5% 2023/05/05 10:44:08 Seeking Alpha
Hercules Capital is a leading BDC lending to venture-backed companies, with a $3 billion loan portfolio. Learn why I rate HCXY stock a hold.
Q1 2023 EPS Estimates for Hercules Capital, Inc. Lifted by Analyst (NYSE:HTGC) 2023/04/22 05:38:49 The AM Reporter
Hercules Capital, Inc. (NYSE:HTGC – Get Rating) – Equities research analysts at Zacks Research lifted their Q1 2023 earnings estimates for Hercules Capital in a research note issued on Wednesday, April 19th. Zacks Research analyst N. Kataruka now expects that the financial services provider will earn $0.43 per share for the quarter, up from their […]
Hercules Capital Mentioned Cautiously at Bear Cave 2023/04/20 14:34:03 Investing.com
https://www.investing.com/news/pro/hercules-capital-mentioned-cautiously-at-bear-cave-432SI-3060670
Hercules Capital Announces Date for Release of First Quarter 2023 Financial Results and Conference Call 2023/04/20 10:00:00 Wallstreet:Online
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its first quarter 2023 financial results conference call for Thursday, May 4,
Wells Fargo maintains Hercules Capital at Overweight, PT $13.00 2023/04/18 14:07:36 Investing.com
https://www.investing.com/news/pro/hercules-tech-growth-capital-receives-investment-bank-analyst-rating-update-3058172
Hercules Capital upgraded to Overweight at Piper Sandler after recent selloff 2023/04/06 14:12:30 Seeking Alpha
Hercules Capital (HTGC) stock rose 1.6% in Thursday morning trading after Piper Sandler analyst Crispin Love upgraded the business development company to Overweight. Read more here.
Hercules Capital upgraded to Overweight at Piper Sandler after recent selloff 2023/04/06 14:12:30 Seeking Alpha
Hercules Capital (HTGC) stock rose 1.6% in Thursday morning trading after Piper Sandler analyst Crispin Love upgraded the business development company to Overweight. Read more here.
Piper Sandler upgrades Hercules Capital to Overweight 2023/04/06 08:56:35 Investing.com
https://www.investing.com/news/pro/hercules-tech-growth-capital-receives-investment-bank-analyst-rating-update-3050166
Hercules Capital''s private credit move applauded at Piper Sandler 2023/03/27 18:29:45 Seeking Alpha
Hercules Capital (HTGC) trades ~4% higher after Piper Sandler sees positives in the launch of a new private credit lending business line to support the venture and growth stage…
Hercules Capital subsidiary launches a new institutional private credit lending program 2023/03/27 10:35:52 Seeking Alpha
Hercules Adviser LLC, a wholly-owned subsidiary of Hercules Capital (HTGC) has established a new institutional private credit lending program to support venture and growth stage…
Atai Life Sciences Hopes Hercules Can Help ''Sustain'' Operations Until 2026 2023/03/24 17:32:53 Benzinga
Biopharma company Atai Life Sciences'' (NASDAQ: ATAI ) fourth quarter and full year 2022 consolidated financial results show: Cash, cash equivalents, and short-term investments totaling $273.1 million as of Dec. 31, 2022, lower than the $362.3 million in Dec. 31, 2021. The company expects its term loan facility with Hercules Capital Inc. to sustain operations into the first half of 2026. R&D expenses totaled $21.9 million and $74.3 million for the three and twelve months ended Dec. 31, 2022, respectively, as compared to $13 million and $48.0 million for the same periods in 2021. G&A expenses were $15.7 … Full story available on Benzinga.com